CTOs on the Move

InterveXion Therapeutics

www.intervexion.com

 
At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

InterveXion Therapeutics raised $13.8M on 11/01/2021

Similar Companies

Immunocore

Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.

IGM Biosciences

IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM and IgA antibodies that improve the treatment of cancer and other diseases since 2010.

Copan Diagnostics

Copan Diagnostics is a Murrieta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory, Inc is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.